XML 38 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Revenues from Contracts with Customers
12 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenues from Contracts with Customers

3. Revenues from Contracts with Customers

The Company disaggregates its revenue into two segments, the Rx Segment and the Consumer Health Segment. The Rx Segment includes the ADHD Portfolio, comprised of Adzenys XR-ODT and Cotempla XR-ODT; and the Pediatric Portfolio, comprised of Poly-Vi-Flor, Tri-Vi-Flor, and Karbinal ER. The Consumer Health portfolio is comprised of over ten consumer health products competing in large healthcare categories.

Revenues by Segment: Net revenue disaggregated by segment for the years ended June 30, 2023 and 2022 were as follows.

Year Ended

June 30, 

    

2023

    

2022

(In thousands)

Rx Segment

 

$

73,799

 

$

61,121

Consumer Health Segment

33,600

35,548

Consolidated revenue

 

$

107,399

 

$

96,669

Revenues by Product Portfolio: Net revenue disaggregated by significant product portfolios in the Rx Segment for the years ended June 30, 2023 and 2022 were as follows.

Year Ended

June 30, 

2023

    

2022

Rx Segment

(In thousands)

ADHD

$

46,855

$

42,855

Pediatric

25,377

16,084

Other

1,567

2,182

$

73,799

$

61,121

Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment is comprised of one product portfolio, the Consumer Health Portfolio.

Revenues by Geographic location. The following table reflects product revenues by geographic location as determined by the billing address of the Company’s customers:

    

Year Ended

June 30, 

    

2023

    

2022

(In thousands)

U.S.

$

106,918

$

94,606

International

 

481

 

2,063

Total net revenue

$

107,399

$

96,669